Unlock instant, AI-driven research and patent intelligence for your innovation.

Therapeutic Cancer Vaccine

Inactive Publication Date: 2013-12-12
CADILA PHARMA
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text is about a new invention that aims to change the way cancer cells behave in order to make them better for immunotherapy. The invention can target specific cancer antigens in different types of cancer, and the result is a therapeutic vaccine that can be used to treat malignant tumors. The vaccine can stimulate both cell-based and humoral immunity against the cancer cells, and it can even be made from allogenic cancer cells that do not cause carcinogenicity. Overall, this invention provides a more effective and personalized approach to cancer treatment.

Problems solved by technology

There is a lack of well defined antigens for organ / tissue specific cancer.
Use of autologus cancer cell in vaccines is personalized therapy and is associated with practical difficulties.
The autologus cells may not be available in ail patients.
When available it may not be of the desired quality and / or quantity.
The approach is also time consuming.
The approach is also associated with regulatory hurdles.
However it suffers from lack of common antigen / s as cancer cells from a tissue / organ are heterogeneous in nature.
However Mia-paca-2 cell line fails to elicit immune response against Panc-1 and Panc-1 fails to elicit immune response against Mia-paca-2
The heterogeneity of tumor makes it difficult to have a therapeutic vaccine with a single antigen to provide immune response against all the cells / majority of cells contained in the tumor.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic Cancer Vaccine
  • Therapeutic Cancer Vaccine
  • Therapeutic Cancer Vaccine

Examples

Experimental program
Comparison scheme
Effect test

example 1

Process of Altering the Immunogenic Profile of Cancer Cells in such a Way that they are Immunogenic Against Heterogeneous Cancer Antigen / s Specific to Tissue / Organ

[0079]A) Allogenic Mia-paca-2 cancer cells are harvested and washed with Dulbelco's

[0080]Phosphate buffer saline (DPBS) to remove traces of serum. Viable cells are counted and “Mycobacterium W” is added to the cells at a cell: “Mycobacterium W” ratio of 1:100. This cell suspension is incubated at 37° C. for 6 hrs. The cell suspension is centrifuged at 350 g for 10 minutes to separate and remove “Mycobacterium W”. The intracellular p38 levels are measured. The cells with increased p38 levels are used as a vaccine or may be further formulated. The adjutant / s may be added to it if desired.[0081]B) Allogenic B16 melanoma cancer cells are harvested and washed with DPBS to remove traces of serum. Viable cells are counted and “Mycobacterium W” is added to the cells at a cell: “Mycobacterium W” ratio of 1:100. This cell suspension...

example 2

Following Example Illustrates Improved Immune Response as per Present Invention without Limiting the Scope of Invention

A. Therapeutic Vaccine Elicits Cell Mediated Immune Response Against Homologous Cancer Cells as Demonstrated by Interferon Gamma ELISPOT.

[0092]Therapeutic Cancer vaccines prepared by the method described in example 1 are immunogenic and elicit a Th1 type of immune response as demonstrated by immunogenicity studies in mouse model. Briefly, mice were immunized intra-dermally with vehicle control or vaccine formulation containing 2×10̂6 cells on day 0 and 21. The animals were euthanized by CO2 over exposure on day 28 and immune status was determined as studied by the number of IFN-g secreting cells amongst splenocytes. A significant increase (8.4 fold) was found in the number of IFN-g secreting cells in the Group immunized with vaccine formulation compared to Vehicle Control as depicted in Table: 1

TABLE 1Immunogenicity of Cancer Vaccine determined bythe number of IFN-g...

example 3

Following Example Illustrates Immune Response Against Heterogeneous Cancer Cells Specific to Tissue / Organ as per Present Invention without Limiting the Scope of Invention

A. Therapeutic Vaccine Elicits Cell Mediated Immune Response Against Heterogeneous Cancer Cells Specific to Tissue / Organ as Demonstrated by ELISPOT-rise in Interferon Gamma Producing Cells

[0096]Mice were immunized intra-dermally with control or 2×106 Mia-para-2 cells for cancer vaccine formulation prepared as in example 1 on day 0 and 21. On day 28 mice were euthanized by over-exposure of CO2. The spleen from each mouse was collected and splenocytes isolated. 5×105 splenocytes from each mice were seeded in ELISPOT plates from R & D Systems coated with capture antibody for IFN-g. The cells were stimulated in-vitro with 10 ug / ml of lysates of Mia-PaCa-2, Panc-1 and AsPC-1 and incubated at 37° C. and 6% CO2 for ˜36 hrs. At the end of the incubation period the plates were developed as per the manufactures instructions. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Therapeuticaaaaaaaaaa
Immunogenicityaaaaaaaaaa
Login to View More

Abstract

The present invention relates to vaccine(s) comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein the said antigen(s) is expressed on contacting the said cancer cell with p38 inducer, for use in treatment of Cancer. The vaccine composition induces specific immune response against homologous and heterologus cancer cells of the tissue / organ. The invention also provides method of preparing the same.

Description

FIELD OF INVENTION[0001]The present invention relates to therapeutic vaccines, for use in treatment of malignant tumors, having immunogenicity against heterogeneous cancer antigen / s specific to tissue / organ. The invention also provides method of preparing the same.BACKGROUND[0002]Malignant tumors are known to have many different types of cells in it. These cells have genes and proteins that are very different from one another. And they grow at different rates. This is known as heterogeneity. The heterogeneity is also responsible for combining chemotherapy with radiotherapy and / or various kind of chemotherapy in combination for effective treatment of malignant tumors.[0003]There is a lack of well defined antigens for organ / tissue specific cancer. To overcome this problem cancer cells are used as an antigen. The use of cancer cells provides benefit of repertoires of the antigens present on cancer cells.[0004]The cancer cells can be sourced from the same patients (autologus) or from a ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/04A61K39/00
CPCA61K39/04A61K39/0011A61K2039/5152A61K2039/55594A61K2039/572A61K2039/575A61P35/00A61P37/04A61K2039/80A61K39/00A61K35/12A61K38/00A61K35/00A61K9/0021A61K2039/54
Inventor KHAMAR, BAKULESH MAFATLALDESAI, NIRAV MANOJKUMARSHUKLA, CHANDRESHWAR PRASADDARJI, AVANI DEVENBHAIMODI, INDRAVADAN AMBALAL
Owner CADILA PHARMA